The popularity of Sildenafil initially fueled a boom for pharma, however recent developments present a uncertain outlook for investors. Generic competitors are reducing revenue, and ongoing litigation add more difficulty to the equation. While certain companies may still gain from related offerings, the general trajectory suggests a measured approa